Eyenuk has secured $26 million in a Series A financing round, bringing the company’s total funding to more than $43 million.
Eyenuk plans to use the funds to expand its AI product platform to include more disease indications and care coordination, as well as to accelerate global commercialization of the platform. The EyeArt AI system received FDA clearance in 2020 for diabetic retinopathy screening.
AXA IM Alts led the funding round, joined by T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall Capital Partners and KOFA Healthcare.
“Our Series A fundraise validates the